Literature DB >> 21050765

Persistence of human papillomavirus infection: keys to malignant progression.

Jason Bodily1, Laimonis A Laimins.   

Abstract

Human papillomaviruses (HPVs) are the etiologic agents of cervical and other epithelial cancers. Persistence of infections by high-risk HPV types is the single greatest risk factor for malignant progression. Although prophylactic vaccines have been developed that target high-risk HPV types, there is a continuing need to understand better the virus-host interactions that underlie persistent benign infection and progression to cancer. In this review we summarize the molecular events that facilitate the differentiation-dependent HPV life cycle, how the life cycle is organized to facilitate virus persistence, and how the activities of HPV regulatory proteins result in malignancy. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21050765      PMCID: PMC3059725          DOI: 10.1016/j.tim.2010.10.002

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  74 in total

1.  Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells.

Authors:  R N Fichorova; D J Anderson
Journal:  Biol Reprod       Date:  1999-02       Impact factor: 4.285

2.  Temporal usage of multiple promoters during the life cycle of human papillomavirus type 31b.

Authors:  M A Ozbun; C Meyers
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

3.  Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b.

Authors:  M A Ozbun; C Meyers
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice.

Authors:  K Smith-McCune; Y H Zhu; D Hanahan; J Arbeit
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

Review 5.  Papillomavirus infections--a major cause of human cancers.

Authors:  H zur Hausen
Journal:  Biochim Biophys Acta       Date:  1996-10-09

6.  Differential requirements for conserved E2 binding sites in the life cycle of oncogenic human papillomavirus type 31.

Authors:  F Stubenrauch; H B Lim; L A Laimins
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein.

Authors:  G Steger; S Corbach
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Colonization of in vitro-formed cervical human papillomavirus- associated (pre)neoplastic lesions with dendritic cells: role of granulocyte/macrophage colony-stimulating factor.

Authors:  P Hubert; F van den Brüle; S L Giannini; E Franzen-Detrooz; J Boniver; P Delvenne
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

9.  Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions.

Authors:  I Arany; S K Tyring
Journal:  Sex Transm Dis       Date:  1996 Nov-Dec       Impact factor: 2.830

10.  Human papillomavirus oncoproteins alter differentiation-dependent cell cycle exit on suspension in semisolid medium.

Authors:  M N Ruesch; L A Laimins
Journal:  Virology       Date:  1998-10-10       Impact factor: 3.616

View more
  138 in total

Review 1.  [HPV-associated squamous cell carcinogenesis].

Authors:  G Assmann; K Sotlar
Journal:  Pathologe       Date:  2011-09       Impact factor: 1.011

Review 2.  Hitchhiking on host chromatin: how papillomaviruses persist.

Authors:  Alison A McBride; Nozomi Sakakibara; Wesley H Stepp; Moon Kyoo Jang
Journal:  Biochim Biophys Acta       Date:  2012-01-28

3.  Heterogeneous Nuclear Ribonucleoprotein C Proteins Interact with the Human Papillomavirus Type 16 (HPV16) Early 3'-Untranslated Region and Alleviate Suppression of HPV16 Late L1 mRNA Splicing.

Authors:  Soniya Dhanjal; Naoko Kajitani; Jacob Glahder; Ann-Kristin Mossberg; Cecilia Johansson; Stefan Schwartz
Journal:  J Biol Chem       Date:  2015-04-15       Impact factor: 5.157

Review 4.  Human papillomavirus and lung cancinogenesis: an overview.

Authors:  Antonio Carlos de Freitas; Ana Pavla Gurgel; Elyda Golçalves de Lima; Bianca de França São Marcos; Carolina Maria Medeiros do Amaral
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-29       Impact factor: 4.553

5.  Cervical cytokines and clearance of incident human papillomavirus infection: Hawaii HPV cohort study.

Authors:  Mark E Scott; Yurii B Shvetsov; Pamela J Thompson; Brenda Y Hernandez; Xuemei Zhu; Lynne R Wilkens; Jeffrey Killeen; Dien D Vo; Anna-Barbara Moscicki; Marc T Goodman
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

Review 6.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

7.  [The STIKO now recommends the HPV vaccination for boys too].

Authors:  Stefanie J Klug; Marianne van der Sande; Martin Terhardt; Fred Zepp; Marianne Röbl-Mathieu; Jörg Meerpohl; Miriam Wiese-Posselt; Thomas Harder; Ole Wichmann; Anja Takla
Journal:  Urologe A       Date:  2018-11       Impact factor: 0.639

8.  Regulation of the human papillomavirus type 16 late promoter by transcriptional elongation.

Authors:  William K Songock; Matthew L Scott; Jason M Bodily
Journal:  Virology       Date:  2017-04-24       Impact factor: 3.616

Review 9.  Human papillomavirus DNA methylation as a potential biomarker for cervical cancer.

Authors:  Megan A Clarke; Nicolas Wentzensen; Lisa Mirabello; Arpita Ghosh; Sholom Wacholder; Ariana Harari; Attila Lorincz; Mark Schiffman; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-03       Impact factor: 4.254

10.  APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers.

Authors:  S Kondo; K Wakae; N Wakisaka; Y Nakanishi; K Ishikawa; T Komori; M Moriyama-Kita; K Endo; S Murono; Z Wang; K Kitamura; T Nishiyama; K Yamaguchi; S Shigenobu; M Muramatsu; T Yoshizaki
Journal:  Oncogene       Date:  2016-10-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.